Estrogenic activity is increased for an antiestrogen by a natural mutation of the estrogen receptor

Journal of Steroid Biochemistry and Molecular Biology

Volumn 60, Issue 5-6, 1997, Pages 261-268

  Levenson, Anait S ^a   Catherino, William H ^b   Jordan, V Craig ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

^b UNIVERSITY OF WISCONSIN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIESTROGEN; ESTRADIOL; ESTROGEN RECEPTOR; FULVESTRANT; MESSENGER RNA; RALOXIFENE; TAMOXIFEN; TRANSCRIPTION FACTOR; TRANSFORMING GROWTH FACTOR ALPHA;

ARTICLE; BREAST CANCER; ESTROGEN ACTIVITY; GENE EXPRESSION; HORMONE RESPONSIVE ELEMENT; HUMAN; HUMAN CELL; MUTATION; NORTHERN BLOTTING; RECEPTOR GENE;

BREAST NEOPLASMS; CELL DIVISION; DOSE-RESPONSE RELATIONSHIP, DRUG; ESTRADIOL; ESTROGEN ANTAGONISTS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MUTATION; PIPERIDINES; RALOXIFENE; RECEPTORS, ESTROGEN; RNA, MESSENGER; RNA, NEOPLASM; TRANSFECTION; TRANSFORMING GROWTH FACTOR ALPHA; TUMOR CELLS, CULTURED;

EID: 0031008040     PISSN: 09600760     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-0760(96)00184-7     Document Type: Article

References (23)

1. Mahfoudi A., Roulet E., Dauvois S., Parker M. G. and Wahli W., Specific mutations in the estrogen receptor change the properties of an antiestrogen to full agonists. Proc. Natl. Acad. Sci. U.S.A. 92 (1995) 4206-4210.
2. Kraus W. L., McInerney E. M. and Katzenellenbogen B. S., Ligand-dependent, transcriptionally productive association of the amino- and carboxyl-terminal regions of a steroid hormone nuclear receptor. Proc. Natl. Acad. Sci. U.S.A. 92 (1995) 12314-12318.
3. Montano M. M., Ekena K., Krueger K. D., Keller A. L. and Katzenellenbogen B. S., Human estrogen receptor ligand activity inversion mutants: receptors that interpret antiestrogens as estrogens and estrogens as antiestrogens and discriminate among different antiestrogens. Molec. Endocr. 10 (1996) 230-241.
4. Wakeling A. E., A new approach to breast cancer therapy - total estrogen ablation with pure antiestrogens. In Long-term Tamoxifen Treatment for Breast Cancer, ed. V. C. Jordan. The University of Wisconsin Press, Madison, WI, 1994, pp. 219-234.
5. Gottardis M. M., Robinson S. P., Satyaswaroop P. G. and Jordan V. C., Contrasting action of tamoxifen on endometrial and breast tumor growth in the athymic mouse. Cancer Res. 48 (1988) 812-815.
6. Gottardis M. M. and Jordan V. C., Development of tamoxifen-stimulated growth of MCF-7 tumors in athymic mice after long-term antiestrogen administration. Cancer Res. 48 (1988) 5183-5187.
7. Osborne C. K., Coronado-Heinsohn E. B., Hilsenbeck S. G., McCue B. L., Wakeling A. E., McClelland R. A., Manning D. L. and Nicholson R. I., Comparison of the effects of a pure steroidal antiestrogen with those of tamoxifen in a model of human breast cancer. J. Natl. Cancer Inst. 87 (1995) 746-750.
8. Bilimoria M. M., Assikis V. J., Muenzner H. D., Wolf D. M., Satyaswaroop P. G. and Jordan V. C., An analysis of tamoxifen-stimulated human carcinomas for mutations in the AF-2 region of the estrogen receptor. J. Steroid Biochem. Molec. Biol. 58 (1996) 479-488.
9. Wolf D. M. and Jordan V. C., Characterization of tamoxifen stimulated MCF-7 tumor variants grown in athymic mice. Breast Cancer Res. Treat. 31 (1994) 117-127.
10. Wolf D. M. and Jordan V. C., The estrogen receptor from a tamoxifen stimulated MCF-7 tumor variant contains a point mutation in the ligand binding domain. Breast Cancer Res. Treat. 31 (1994) 129-138.
11. Catherino W. H., Wolf D. M. and Jordan V. C., A naturally occurring estrogen receptor mutation results in increased estrogenicity of a tamoxifen analogue. Molec. Endocr. 9 (1995) 1053-1063.
12. Lee D. C., Fenton S. E., Berkowitz E. A. and Hissong M. A., Transforming growth factor α: expression, regulation, and biological activities. Pharmacol. Rev. 47 (1995) 51-85.
13. Reddy K. B., Yee D., Hilsenbeck S. G., Coffey R. J. and Osborne C. K., Inhibition of estrogen-induced breast cancer cell proliferation by reduction in autocrine transforming growth factor alpha expression. Cell Growth Differen. 5 (1994) 1275-1282.
14. Levenson A. S. and Jordan V. C., Transfection of human estrogen receptor (ER) cDNA into ER-negative mammalian cell lines. J. Steroid Biochem. Molec. Biol 51 (1994) 229-239.
15. Jiang S. Y. and Jordan V. C., Growth regulation of estrogen receptor-negative breast cancer cells transfected with complementary DNAs for estrogen receptor. J. Natl. Cancer Inst. 84 (1992) 580-591.
16. LaBarca C. and Paigen K., A simple, rapid, and sensitive DNA assay procedure. Analyt. Biochem. 102 (1980) 344-352.
17. Jeng M. H., Jiang S. Y. and Jordan V. C., Paradoxical regulation of estrogen-dependent growth factor gene expression in estrogen receptor (ER) negative human breast cancer cells stably expressing ER. Cancer Lett. 82 (1994) 123-128.
18. Black L. J., Sato M., Rowley E. R., Magee D. E., Bekele A., Williams D. C., Cullinan G. L., Bendele R., Kauffman R. F., Bensch W. R., Frolik C. A., Termine J. D. and Bryant H. U., Raloxifene (LY 139481HCL) prevents bone loss and reduces serum cholesterol without causing uterine hypertrophy in ovariectomized rats. J. Clin. Invest. 93 (1994) 63-69.
19. Black L. J., Jones C. D. and Falcone J. F., Antagonism of estrogen action with a new benzothiophene derived antiestrogen. Life Sci. 32 (1993) 1031-1036.
20. Wakeling A. E., Use of pure antiestrogens to elucidate the mode of action of estrogens. Biochem. Pharmacol 49 (1995) 1545-1549.
21. Kumar V., Green S., Stack G., Berry M., Jin J. R. and Chambon P., Functional domains of the human estrogen receptor. Cell 51 (1987) 941-951.
22. Webster N. J., Green S., Jin J. R. and Chambon P., The hormone-binding domains of the estrogen and glucocorticoid receptors contain an inducible transcription activation function. Cell 54 (1988) 199-207.
23. Gronemeyer H., Benhamou B., Berry M., Bocquel M. T., Gofflo D., Garcia T., Lerouge T., Metzger D., Meyer M. E., Tora L., Vergezac A. and Chambon P., Mechanisms of antihormone action. J. Steroid Biochem. Molec. Biol. 41 (1992) 217-221.